ELTP (Elite Pharmaceuticals) Moat Score: 4/10 (As of Jun. 28, 2026)


ELTP Elite Pharmaceuticals Inc ELTP
44 GF Score
Price $0.40
GF Value $0.57
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Elite Pharmaceuticals Moat Score?

Elite Pharmaceuticals ELTP +2.62% 44 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates ELTP with a GF Score™ of 44/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,030 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 90.68% on this metric.

Elite Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Elite Pharmaceuticals has Narrow Moat: Elite Pharmaceuticals has some valuable intellectual property and patents in the pharmaceutical sector. However, it lacks strong brand strength and significant market share, resulting in a discernible but modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Elite Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Elite Pharmaceuticals  (OTCPK:ELTP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Elite Pharmaceuticals Moat Score Related Terms

ELTP vs SIGA, ORGO, EOLS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elite Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Moat Score falls into.


ELTP
44GF Score
Elite Pharmaceuticals Inc ELTP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Elite Pharmaceuticals (ELTP) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Elite Pharmaceuticals ranks #96 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Elite Pharmaceuticals' Moat Score too high?
Elite Pharmaceuticals' current Moat Score is 4. Based on the distribution chart, Elite Pharmaceuticals ranks #96 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Moat Score compare to SIGA and ORGO?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #96 out of 1030 companies for Moat Score. This places Elite Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Elite Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.40 — trading 30.7% below its estimated fair value. The current Moat Score is 4. Elite Pharmaceuticals' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.40 is trading 30.7% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • Moat Score: 4
  • GF Value™: $0.57 vs. price of $0.40 (30.7% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
44GF Score

Get the complete analysis for ELTP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.57
GF Value